Trump to withdraw Musk's ally as nominee to head NASA
WASHINGTON: US President Donald Trump said Saturday he was withdrawing his nomination of tech billionaire Jared Isaacman, a close ally of Elon Musk, to lead space agency NASA.
Trump said last December, before returning to office, that he wanted the online payments entrepreneur and the first private astronaut to conduct a spacewalk to serve as the next head of NASA.
But on Saturday, he said on his Truth Social platform that "after a thorough review of prior associations, I am hereby withdrawing the nomination of Jared Isaacman to head NASA."
"I will soon announce a new Nominee who will be Mission aligned, and put America First in Space."
Featured Videos
Earlier, the New York Times had reported the move was coming, quoting unnamed sources as saying the decision had come after the president learned Isaacman had donated money to prominent Democrats.
Asked about that report, the White House had told AFP in an email that it was "essential that the next leader of NASA is in complete alignment with President Trump's America First agenda."
"The Administrator of NASA will help lead humanity into space and execute President Trump's bold mission of planting the American flag on the planet Mars," it said.
The nomination shakeup appears to be a snub of billionaire Musk, who on Friday stepped back from his role leading Trump's so-called Department of Government Efficiency (DOGE).
Musk reportedly lobbied directly with the president for Isaacman, who has had significant business dealings with Musk's SpaceX, to get the top NASA job, raising questions of possible conflicts of interest.
As the news surfaced, Musk stressed on X that "it is rare to find someone so competent and good-arted".
The 42-year-old founder and CEO of Shift4 Payments has emerged as a leading figure in commercial spaceflight through his high-profile collaborations with SpaceX.
He made history last September by stepping out of a Crew Dragon to gaze at Earth from the void of space while gripping the spacecraft's exterior, during the first-ever spacewalk carried out by non-professional astronauts. - AFP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
19 minutes ago
- The Sun
Trump ‘open' to meeting leaders of Ukraine, Russia to push ceasefire
ISTANBUL: US President Donald Trump is 'open' to meeting his Russian and Ukrainian counterparts in Turkey, the White House said, after the two sides failed on Monday to make headway towards an elusive ceasefire. Delegations from both sides did, however, agree another large-scale prisoner exchange in their meeting in Istanbul, which in mid-May also hosted their first round of face-to-face talks. Turkish President Recep Tayyip Erdogan proposed that Russian President Vladimir Putin, Ukrainian President Volodymyr Zelensky and Trump come together for a third round later this month in either Istanbul or Ankara. Putin has thus far refused such a meeting. But Zelensky has said he is willing, underlining that key issues can only be resolved at leaders-level. Trump, who wants a swift end to the three-year war, 'is open to it (a three-way summit) if it comes to that, but he wants both of these leaders and both sides to come to the table together', White House spokeswoman Karoline Leavitt said in Washington. Zelensky said that 'we really expect Trump to take strong steps', and urged the US leader to toughen sanctions on Russia to 'push' it to agree to a full ceasefire. In Monday's meeting, Ukraine said that Moscow had rejected its call for an unconditional ceasefire. It offered instead a partial truce of two to three days in some areas of the frontline. Russia will only agree a full ceasefire if Ukrainian troops pull back entirely from four regions, -- Donetsk, Lugansk, Zaporizhzhia and Kherson -- according to its negotiating terms reported on by Russian state media. Russia currently only partly controls those regions. Moscow has also demanded a ban on Kyiv joining NATO, limiting Ukraine's military and ending Western military support. Prisoner swap Top negotiators from both sides confirmed their latest talks yielded a deal to swap all severely wounded soldiers as well as all captured fighters under the age of 25. Russia's lead negotiator Vladimir Medinsky said it would involve 'at least 1,000' on each side -- topping the 1,000-for-1,000 POW exchange agreed at talks last month. The two sides also agreed to hand over the bodies of 6,000 killed soldiers, Ukraine said after the talks. 'The Russian side continued to reject the motion of an unconditional ceasefire,' Ukraine's Deputy Foreign Minister Sergiy Kyslytsya told reporters after the talks. Russia said it had offered a limited pause in fighting. 'We have proposed a specific ceasefire for two to three days in certain areas of the front line,' top negotiator Vladimir Medinsky said, adding that this was needed to collect the bodies of dead soldiers from the battlefield. Kyiv said it would study a document the Russian side handed its negotiators outlining its demands for both peace and a full ceasefire. Zelensky said after the Istanbul talks concluded that any deal must not 'reward' Putin. 'The key to lasting peace is clear, the aggressor must not receive any reward for war,' Zelensky said at a press conference in Vilnius alongside several NATO leaders. The Ukrainian president has said a long-term peace deal can only happen once fighting has paused, and has called for an immediate and unconditional ceasefire to cover combat on air, sea and land. 'Constructive atmosphere' Ukrainian Defence Minister Rustem Umerov, who led his country's delegation, called for a next meeting to take place before the end of June. He also said a Putin-Zelensky summit should be discussed. Turkish Foreign Minister Hakan Fidan said after the talks -- inside a luxury hotel on the banks of the Bosphorus -- that they were held 'in a constructive atmosphere'. 'The parties built on the points they had agreed upon during the first meeting,' Fidan said on X. 'During the meeting, the parties decided to continue preparations for a possible meeting at the leader level,' he said. Tens of thousands have been killed since Russia invaded, with swathes of eastern and southern Ukraine destroyed and millions forced to flee their homes in Europe's largest refugee crisis since World War II. In the front-line town of Dobropillya in eastern Ukraine, 53-year-old Volodymyr told AFP he had no hope left for an end to the conflict. 'We thought that everything would stop. And now there is nothing to wait for. We have no home, nothing. We were almost killed by drones,' he said. After months of setbacks for Kyiv's military, Ukraine said it had carried out an audacious attack on Sunday, smuggling drones into Russia and then firing them at airbases, damaging around 40 strategic Russian bombers worth $7 billion in a major special operation.
The Sun
20 minutes ago
- The Sun
Trump and Xi will likely speak this week, White House says
WASHINGTON: President Donald Trump and Chinese leader Xi Jinping will likely speak this week, White House press secretary Karoline Leavitt said on Monday, days after Trump accused China of violating an agreement to roll back tariffs and trade restrictions. Leavitt is the third top Trump aide to forecast an imminent call between the two leaders to iron out differences on last month's tariff agreement in Geneva, among larger trade issues. It was not immediately clear when the two leaders will speak. U.S. Treasury Secretary Scott Bessent told CBS' 'Face the Nation' on Sunday that Trump and Xi would speak 'very soon' to iron out trade issues including a dispute over critical minerals and China's restrictions on exports of certain minerals. Trump said on Friday he was sure that he would speak to Xi. China said in April that the two leaders had not had a conversation recently. On Saturday, the U.S. Trade Representative's office announced it would continue to exclude certain solar manufacturing equipment and other products from existing tariffs on Chinese goods until August 31, offering a three-month extension while talks with Beijing continue. Bessent led negotiations with China in Geneva last month that resulted in a temporary truce in the trade war between the world's two biggest economies, but progress since then has been slow, the U.S. Treasury chief told Fox News last week. The U.S.-China agreement to dial back triple-digit tariffs for 90 days prompted a massive relief rally in global stocks. But it did nothing to address the underlying reasons for Trump's tariffs on Chinese goods, mainly longstanding U.S. complaints about China's state-dominated, export-driven economic model, leaving those issues for future talks. A U.S. trade court on Wednesday ruled that Trump overstepped his authority in imposing the bulk of his tariffs on imports from China and other countries under an emergency powers act. But less than 24 hours later, a federal appeals court reinstated the tariffs, saying it was pausing the trade court ruling to consider the government's appeal. The appeals court ordered the plaintiffs to respond by June 5 and the administration to respond by June 9.
New Straits Times
20 minutes ago
- New Straits Times
New hope for patients with less common breast cancer
WASHINGTON: A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer – the advanced stage of a form that comprises 15–20 per cent of all breast cancer cases. HER2-positive cancers are fuelled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. "Seeing such a striking improvement was really impressive to us – we were taking a standard and almost doubling how long patients could have their cancer controlled for," said oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, speaking to AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney. "Some people call them smart bombs because they're delivering chemo in a targeted fashion – which is how I think we're able to really increase efficacy so much." Common side effects included nausea, diarrhoea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a "second-line" option – used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled – but those results haven't yet been reported. At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 per cent compared to standard care. Fifteen per cent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 per cent in the THP group. Because this was an interim analysis, the median progression-free survival – meaning the point at which half the patients had seen their cancer return or worsen – was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimising how long patients remain on the treatment, particularly those showing complete remission. "This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study.
